卡那奴单抗与安慰剂对重症COVID-19住院患者无创机械通气生存率的影响:一项随机临床试验
这项在欧美39家医院开展的随机双盲安慰剂对照3期试验纳入454例COVID-19肺炎、低氧(未需要有创机械通气)且全身炎症标志物升高的住院患者,1:1随机接受单次静脉卡那奴单抗(按体重450/600/750 mg)或安慰剂。COVID-19相关死亡率和严重不良事件两组间亦无显著差异。
要点
- COVID-19相关死亡率:卡那奴单抗组4.9% vs 安慰剂组7.2%,率差-2.3%(95%CI -6.7%至2.2%),OR 0.67(95%CI 0.30-1.50),无显著差异。
- 严重不良事件发生率:卡那奴单抗组16%(36/225) vs 安慰剂组20.6%(46/223)。
- 适用人群:住院COVID-19肺炎、低氧但未需要有创机械通气、CRP或铁蛋白升高的成人患者(体重40 kg以上)。
- 给药方案:单次静脉输注,体重40-<60 kg用450 mg,60-80 kg用600 mg,>80 kg用750 mg。
适用人群与场景
- 住院COVID-19肺炎、低氧(未需要有创机械通气)、全身炎症反应(血CRP或铁蛋白升高)的成人患者。
- 体重40 kg以上;排除需有创机械通气者。
- 试验在欧美39家医院进行,2020年4月30日至8月17日入组。
诊断标准与关键阈值
- 全身炎症反应定义为血C反应蛋白或铁蛋白浓度升高(原文未给出具体界值)。
- 低氧定义为不需要有创机械通气(原文未给出具体氧合阈值)。
处置流程与药物剂量
- 单次静脉输注卡那奴单抗:体重40-<60 kg用450 mg,60-80 kg用600 mg,>80 kg用750 mg。
- 对照组接受安慰剂单次静脉输注。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 随机双盲安慰剂对照3期试验,39家医院,454例患者(卡那奴单抗227例,安慰剂227例),中位年龄59岁,女性41.2%。
- COVID-19相关死亡率:卡那奴单抗组11/223(4.9%) vs 安慰剂组16/222(7.2%),率差-2.3%(95%CI -6.7%至2.2%),OR 0.67(95%CI 0.30-1.50)。
- 严重不良事件:卡那奴单抗组36/225(16%) vs 安慰剂组46/223(20.6%)。
- 417例(91.9%)完成第29天评估。
证据类型、等级与局限
- 随机双盲安慰剂对照3期试验,证据等级高,但主要终点无统计学显著差异。
- 局限:入组时间2020年4-8月,可能不反映当前变异株和治疗背景;样本量454例,事件数较少,次要终点置信区间宽。
对床旁实践的改变
- 对于重症COVID-19住院患者,卡那奴单抗单次静脉输注未显著改善第29天无创机械通气生存率,不改变现有治疗实践。
- 不应将卡那奴单抗作为重症COVID-19的常规治疗。
- 适用人群为低氧但未需要有创机械通气且炎症标志物升高的患者,不适用于已需要有创机械通气者。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Effective treatments for patients with severe COVID-19 are needed.
OBJECTIVE: To evaluate the efficacy of canakinumab, an anti-interleukin-1β antibody, in patients hospitalized with severe COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States. A total of 454 hospitalized patients with COVID-19 pneumonia, hypoxia (not requiring invasive mechanical ventilation [IMV]), and systemic hyperinflammation defined by increased blood concentrations of C-reactive protein or ferritin were enrolled between April 30 and August 17, 2020, with the last assessment of the primary end point on September 22, 2020.
INTERVENTION: Patients were randomly assigned 1:1 to receive a single intravenous infusion of canakinumab (450 mg for body weight of 40-<60 kg, 600 mg for 60-80 kg, and 750 mg for >80 kg; n = 227) or placebo (n = 227).
MAIN OUTCOMES AND MEASURES: The primary outcome was survival without IMV from day 3 to day 29. Secondary outcomes were COVID-19-related mortality, measurements of biomarkers of systemic hyperinflammation, and safety evaluations.
RESULTS: Among 454 patients who were randomized (median age, 59 years; 187 women [41.2%]), 417 (91.9%) completed day 29 of the trial. Between days 3 and 29, 198 of 223 patients (88.8%) survived without requiring IMV in the canakinumab group and 191 of 223 (85.7%) in the placebo group, with a rate difference of 3.1% (95% CI, -3.1% to 9.3%) and an odds ratio of 1.39 (95% CI, 0.76 to 2.54; P = .29). COVID-19-related mortality occurred in 11 of 223 patients (4.9%) in the canakinumab group vs 16 of 222 (7.2%) in the placebo group, with a rate difference of -2.3% (95% CI, -6.7% to 2.2%) and an odds ratio of 0.67 (95% CI, 0.30 to 1.50). Serious adverse events were observed in 36 of 225 patients (16%) treated with canakinumab vs 46 of 223 (20.6%) who received placebo.
CONCLUSIONS AND RELEVANCE: Among patients hospitalized with severe COVID-19, treatment with canakinumab, compared with placebo, did not significantly increase the likelihood of survival without IMV at day 29.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04362813.
参考来源
- Caricchio R, Abbate A, Gordeev I, et al. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021. PMID: 34283183. doi:10.1001/jama.2021.9508
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。